MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
40.00
-0.35
-0.87%
After Hours: 40.00 0 0.00% 16:32 07/18 EDT
OPEN
40.70
PREV CLOSE
40.35
HIGH
41.19
LOW
39.96
VOLUME
824.65K
TURNOVER
--
52 WEEK HIGH
62.58
52 WEEK LOW
23.42
MARKET CAP
2.32B
P/E (TTM)
3.544
1D
5D
1M
3M
1Y
5Y
1D
Director David Scadden Reports Disposal of Common Shares of Agios Pharmaceuticals Inc
Reuters · 4d ago
Weekly Report: what happened at AGIO last week (0707-0711)?
Weekly Report · 5d ago
Agios Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Jay T. Backstrom
Reuters · 07/10 20:12
Agios Pharma Appoints Dr. Jay Backstrom as Director
TipRanks · 07/08 11:30
Agios Pharmaceuticals appoints Jay Backstrom to board
TipRanks · 07/08 11:15
AGIOS APPOINTS DR. JAY BACKSTROM TO BOARD OF DIRECTORS
Reuters · 07/08 11:00
Press Release: Agios Appoints Dr. Jay Backstrom to Board of Directors
Dow Jones · 07/08 11:00
Weekly Report: what happened at AGIO last week (0630-0704)?
Weekly Report · 07/07 09:02
More
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

Webull offers Agios Pharmaceuticals Inc stock information, including NASDAQ: AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.